Marcel Lucas Almeida

Dr. Marcel Lucas Almeida

Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in Current Organic Synthesis
Verified
Journal Article
Closed access
PDF file
Marcel Lucas AlmeidaMarcel Lucas Almeida
Marcel Lucas Almeida
MOMaria C.V.A. Oliveira
Maria C.V.A. Oliveira
IPIvan da Rocha Pitta
Ivan da Rocha Pitta
MPMarina Pitta
Marina Pitta
Phthalimide derivatives have been presenting several promising biological activities in the literature, such as anti-inflammatory, analgesic, antitumor, antimicrobial and anticonvulsant. The most well-known and studied phthalimide derivative (isoindoline-1,3-dione) is thalidomide: this compound initially presented important sedative effects, but it is now known that thalidomide has effectiveness against a wide variety of diseases, including inflammation and cancer. This review approaches some of the recent and efficient chemical synthesis pathways to obtain phthalimide analogues and also presents a summary of the main biological activities of these derivatives found in the literature. Therefore, this review describes the chemical and therapeutic aspects of phthalimide derivatives.

17 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marcel Lucas AlmeidaMarcel Lucas Almeida
Marcel Lucas Almeida
AMAna Paula dos Santos Matos
Ana Paula dos Santos Matos
Veronica da Silva CardosoVeronica da Silva Cardoso
Veronica da Silva Cardoso
TNTatielle Do Nascimento
Tatielle Do Nascimento
RSRalph Santos-Oliveira
Ralph Santos-Oliveira
EREduardo Ricci Ricci-Júnior
Eduardo Ricci Ricci-Júnior
Background/Objectives: Candidiasis, primarily caused by Candida albicans, and sporotrichosis, mainly caused by Sporothrix schenckii, are skin fungal infections that pose serious threats to global health. The Candida auris is a great concern in immunocompromised individuals, and while Sporothrix brasiliensis cause sporotrichosis, an infection commonly found in cats, this disease can be transmitted to humans through scratches or bites. Existing treatments for these fungal infections often cause problems related to resistance and significant side effects. Consequently, development of alternative therapeutic approaches such as nanotechnology-based topical lipid-based formulations is interesting. Thus, the objectives of this study were to prepare clove oil (CO)-in-water nanoemulsions (NEs) containing amphotericin B (AmB) and characterize them with respect to stability, release profile, and in vitro cytotoxic activity against Candida and Sporothrix strains. As a future alternative for the treatment of fungal skin diseases. Methods: Chemical analysis of clove oil was obtained by GC-MS. The NEs were produced using an ultrasound (sonicator) method with varying proportions of CO, Pluronic® F-127, and AmB. The NEs were characterized by droplet size, morphology, stability and in vitro release profile. The antifungal and cytotoxic activity against C. albicans, C. auris, S. schenckii, and S. brasiliensis were ascertained employing agar diffusion and colorimetric MTT assay methods. A checkerboard assay was carried out using clove oil and amphotericin B against C. auris. Results: Eugenol was the major compound identified in CO at a concentration of 80.09%. AmB-loaded NEs exhibited particle sizes smaller than 50 nm and a polydispersity index below 0.25. The optimal Ne (NEMLB-05) remained stable after 150 days of storage at 4 °C. It exhibited rapid release within the first 24 h, followed by a slow and controlled release up to 96 h. NEMLB-05 more effectively inhibited C. auris compared to free AmB and also demonstrated greater activity against C. albicans, S. schenckii, and S. brasiliensis. Clove oil and amphotericin B presented synergism inhibiting the growth of C. auris. Conclusions: The selected CO-in-water NEs containing AmB demonstrated promising potential as a topical therapeutic alternative for treating fungal infections.

17 November 2021 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
FSFlaviana A. Santos
Flaviana A. Santos
Marcel Lucas AlmeidaMarcel Lucas Almeida
Marcel Lucas Almeida
VSVitor A. S. Silva
Vitor A. S. Silva
DVDouglas Viana
Douglas Viana
MPMichelly Cristiny Pereira
Michelly Cristiny Pereira
IPIvan da Rocha Pitta
Ivan da Rocha Pitta

9 July 2020 in Combinatorial Chemistry & High Throughput Screening
Verified
Journal Article
Closed access
PDF file
Marcel Lucas AlmeidaMarcel Lucas Almeida
Marcel Lucas Almeida
DVDouglas C.F. Viana
Douglas C.F. Viana
VCValécia C.M. da Costa
Valécia C.M. da Costa
FSFlaviana A. dos Santos
Flaviana A. dos Santos
MPMichelly C. Pereira
Michelly C. Pereira
MPMarina G.R. Pitta
Marina G.R. Pitta
Aim and Objective: In the last decades, cancer has become a major problem in public health all around the globe. Chimeric chemical structures have been established as an important trend on medicinal chemistry in the last years. Thiazacridines are hybrid molecules composed of a thiazolidine and acridine nucleus, both pharmacophores that act on important biological targets for cancer. By the fact it is a serious disease, seven new 3-acridin-9-ylmethyl-thiazolidine-2,4-dione derivatives were synthesized, characterized, analyzed by computer simulation and tested in tumor cells. In order to find out if the compounds have therapeutic potential. Materials and Methods: Seven new 3-acridin-9-ylmethyl-thiazolidine-2,4-dione derivatives were synthesized through Michael addition and Knoevenagel condensation strategies. Characterization was performed by NMR and Infrared spectroscopy techniques. Regarding biological activity, thiazacridines were tested against solid and hematopoietic tumoral cell lines, namely Jurkat (acute T-cell leukemia); HL-60 (acute promyelocytic leukemia); DU 145 (prostate cancer); MOLT-4 (acute lymphoblastic leukemia); RAJI (Burkitt's lymphoma); K562 (chronic myelogenous leukemia) and normal cells PBMC (healthy volunteers). Molecular docking analysis was also performed in order to assess major targets of these new compounds. Cell cycle and clonogenic assay were also performed. Results: Compound LPSF/AA-62 (9f) exhibited the most potent anticancer activity against HL-60 (IC50 3,7±1,7 μM), MOLT-4 (IC50 5,7±1,1 μM), Jurkat (IC50 18,6 μM), Du-145 (IC50 20±5 μM) and Raji (IC50 52,3±9,2 μM). While the compound LPSF/AA-57 (9b) exhibited anticancer activity against the K562 cell line (IC50 51,8±7,8 μM). Derivative LPSF/AA-62 (9f) did not interfere in the cell cycle phases of the Molt-4 lineage. However, the LPSF/AA-62 (9f) derivative significantly reduced the formation of prostate cancer cell clones. The compound LPSF/AA-62 (9f) has shown strong anchorage stability with enzymes topoisomerases 1 and 2, in particular due the presence of chlorine favored hydrogen bonds with topoisomerase 1. Conclusion: The 3-(acridin-9-ylmethyl)-5-((10-chloroanthracen-9-yl)methylene)thiazolidine-2,4-dione (LPSF/AA-62) presented the most promising results, showing anti-tumor activity in 5 of the 6 cell types tested, especially inhibiting the formation of colonies of prostate tumor cells (DU-145).

22 April 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
LCLílian Rodrigues Moreira Fraga Couto
Lílian Rodrigues Moreira Fraga Couto
DLDanilo Albuquerque de Lima
Danilo Albuquerque de Lima
BBBreno de Almeida Bertassoni
Breno de Almeida Bertassoni
Marcel Lucas AlmeidaMarcel Lucas Almeida
Marcel Lucas Almeida
FKFranklin Chimaobi Kenechukwu
Franklin Chimaobi Kenechukwu
EREduardo Ricci Ricci-Júnior
Eduardo Ricci Ricci-Júnior